San Diego Stock Exchange

SEARCH SAN DIEGO STOCKS:

Symbol

LA JOLLA PHARMACEUTICAL CO

Symbol	Name	Close	Change		Volume	Dayhigh	Daylow
LJPC	La Jolla Pharma	0.07	0.00	+ 0.00%	1509747.00	0.07	0.06

Exchange	Earningspershare	52-Week High	52-Week Low
NASDAQ N-Mkt	-1.26	3.20	0.04

SourceBook Information

La Jolla Pharmaceutical Co. is listed in:

• Biomed & Biotech Firms -
• Biomed & Biotech Firms - Publicly Traded -
• Highest Paid CEOs of BIO Tech Companies -
• Local Publicly Traded Companies -

Contact Information

Company Name

La Jolla Pharmaceutical Co.

Executives

Deirdre Gillespie, M.D., President/CEO

Niv Caviar, Excutive VP?Cief Business and Financial Officer

Address

6455 Nancy Ridge Drive

San Diego, CA 92121

Phone

(858) 452-6600

Fax

(858) 452-6893

E-mail

n/a

Web Page

www.ljpc.com

Business Information

Parent Company

n/a

SIC Code

3841

Headquarters

San Diego, CA

Local Mailing Address

6455 Nancy Ridge Drive, San Diego, CA 92121

Year Established

1989

Year Established in San Diego

1989

Publicly Traded?

Yes

Ticker Symbol

LJPC

Total Number of Employees

151

Number of Local Employees

n/a

Number of Offices Local

n/a

Gross Revenue 2003 Year End

wnd

Business Description

A biotechnology company leading the development of therapeutics for antibody-mediated autoimmune diseases afflicting several million people in the United States and Europe.

Gross Revenue 2002 Year End

wnd

Business Services

Dedicated to improving and preserving human life by developing innovative pharmaceutical products

Industries of Interest

Biotechnology & drugs

Market Capitalization

$5,257,812

Gross Revenue 2000

$0

Gross Revenue 2000 Year End

wnd

Gross Revenue 2001

$0

Gross Revenue 2001 Year End

wnd

Gross Revenue 2002

$30,400,000

Gross Revenue 2003

$0

Gross Revenue 2004

n/a

Gross Revenue 2005 YTD, Local

n/a

Gross Revenue 2007

n/a

Manufacturer

Yes

Fields of Research

Antibody-mediated diseases

Major Products

Riquent, Toleragen, LJP 1082

Major Investors

Columbia Wanger Asset, Mazama Capital, Alta Partners, Fortis Investments, Deerfield, Barclays Global, Narragansett Management, Sage Asset Dimensional Fund Advisors, Federated Investors

Number of Products Approved For Sale

0

Patents

n/a

Number of Products In Development

2

Strategic Alliances

n/a

Services Offered

n/a

Chief Executive Officer

Deirdre Gillespie

Date CEO Began

2006

Total Annual CEO Compensation (salary & bonuses)

$563,000 (FY 2004)

CEO Salary

$419,000 (FY 2004)

CEO Bonuses

$144,000 (FY 2004)

Gross Revenue 2006

n/a

Sales for 2006

n/a

Gross Revenue 2008

n/a

Mission Statement

n/a